Show newer

RT @CoukosGeorge@twitter.com

TIL Therapy Entering the Mainstream pubmed.ncbi.nlm.nih.gov/364770
Delighted to have contributed this editorial. An important step forward for TIL therapy. Congrats to the NKI and Herlev H teams of John Haanen and Inge-Marie Svane. And a big thanks to Steve Rosenberg and colleagues!

🐦🔗: twitter.com/CoukosGeorge/statu

"By becoming our university’s next 'poster person' and participating in our own tokenization, we allow institutions to paint a rosy picture and appear more inclusive and supportive than they actually are."

Raul Ramos discusses the challenges that come with being held up as a “role model” for your community and how he found the strength to keep going. elifesciences.org/articles/851

My latest column for is a look at early human results of a new class of for

The mechanism of action is essentially to clog the 's tRNA synthetase - the result of two decades of research on boron-based compounds.


nature.com/articles/d41591-022

"Bias and discrimination are rife in master’s and PhD programmes worldwide, a Nature survey finds."

"Some 35% of respondents from minority racial or ethnic groups say that they have experienced discrimination or harassment during their current programme (see ‘Minority report’). That’s more than twice the rate reported by respondents who do not identify as members of those groups (15%)."

nature.com/articles/d41586-022

tho always weird to give a seminar to myself, it's done! have a listen here if you like: youtu.be/i0GAhB3a2F8
the 2nd half is *unpublished* data on #tissue #CD4 #Tcells during #influenza and how they fit into a network of #CD8 #Bcells, #IgA & #NKcells.

I've received feedback from someone working on tumors that some of it brings new perspective on his data. In return I learned some new stuff about bladder cancer.

This open exchange of ideas is why I'm a scientist.

Introducing @emboreports to the fediverse!
 
We are a society-owned primary @EMBOPress #research #journal publishing papers, reviews and science & society commentaries from all areas of molecular #LifeScience #cellbiology #biochemistry #molecularbiology #immunology #microbiology #cancer #development #structure #signaling and many more.
 
Check us out: embor.embopress.org

We're up next for #globalimmuno talk this Wednesday, November 30th at 9am PST, noon EST, 5pm GMT. It says #Tcells but there will be some #Bcells and #NKcells too!

Title: "CD4 T cells Sans Frontières"
LINK: ucsd.zoom.us/j/91053505061

RT @fabian_theis@twitter.com

1/n Single-cell data analysis is complex with many tools to choose from - but which ones work best and should be used when? Led by @lukasheumos@twitter.com and @AnnaCSchaar@twitter.com, we wrote a free online book that aims to guide single-cell data analysts: sc-best-practices.org

🐦🔗: twitter.com/fabian_theis/statu

This week's special issue on #CellEngineering in #Science (@sciencemagazine) includes:

• a review on future of engineered #immunotherapies by Darrell Irvine, Marcela Maus, David Mooney, & Wilson Wong: bit.ly/Sci_abq6990

• a piece on engineering #bacteria for anti- #cancer therapies by
Candice Gurbati, Nick Arpaia, & Tal Danino: bit.ly/Sci_add9667

Be sure to also check out the introduction written by my fantastic colleagues Bryan Ray & Priscilla Kelly: bit.ly/Sci_adf8627

RT @CKemperLab@twitter.com

Hi all. We're happy to share our latest paper, just published in @CellReports@twitter.com. We developed a scRNA-seq pathway analysis package and applied it to look at T cell activation in vitro and in tissue. Here's the paper: cell.com/action/showPdf?pii=S2.

🐦🔗: twitter.com/CKemperLab/status/

black #lymph nodes (draining lung) due to accumulation of environmental pollutants in #macrophages. increases with age. work by Donna Farber lab #ColumbiaUniversity nature.com/articles/s41591-022

Bringing V(D)J analysis to the single-cell space is difficult. We continued to developed dandelion to help with this, finding some interesting new biology along the way in this new pre-print! @Cambridge_Uni@twitter.com @sangerinstitute@twitter.com @ClatworthyLab@twitter.com @teichlab@twitter.com biorxiv.org/content/10.1101/20

If you're looking for some quality science writing, my friend Olivia Judson has a new piece over at Aeon (no paywall).

"Darwin, of course, is famous for his work on evolution. His book On the Origin of Species (1859) laid out a wealth of evidence that evolution occurs, and proposed a mechanism – natural selection – for how it does so. Although much has been learned since, and many of his ideas have been extended, corrected or refined, the Origin remains the founding text of modern biology, and is the pinnacle of Darwin’s work. But Darwin’s first scientific monograph and his last – the two bookends of his thoughts, so to speak – were both about how animals have, over vast spans of time, transformed the landscape."

aeon.co/essays/the-insight-of-

I'll be teaching an one-line :rstats: Bioconductor for Mass Spectrometry and Proteomics course on the 27 - 29 March 2023:

physalia-courses.org/courses-w

If you want to learn on your own, all the software and the material is openly available at:

rformassspectrometry.github.io

#Bioconductor #rstats #MassSpectrometry #Proteomics

New #colitis study from LJI's Kronenberg Lab: frontiersin.org/articles/10.33

The team investigated whether increased expression of two GPRs (GPR183 and GPR18) in the intestine is related to disease severity in colitis models.

#Immunology #Tcells #ImmuneSystem #CellularBiology #MolecularBiology #GPRs #infammation #BowelDisease #Health #MouseModels

My latest Clinical Pipeline column at is just out.

This was an interesting piece for me, to see what's going with drugs targeting family molecules in a clinical setting, in this case an activin receptor 2a/IgG1 Fc domain fusion protein selectively mopping up ligands. The drug's been through trials in oncology, thalassemia & other conditions, but it looks like it had a good hit in pulmonary arterial .

nature.com/articles/d41591-022

Just getting set up on here. Looking forward to connecting with the #immunology #science mastodon community!

"Big trials are expensive, so you can either avoid diseases with big trials or try to argue for ways to make them smaller (through surrogate endpoints, perhaps, or with fewer arms in the dosing groups). But those shortcuts will invariably give you (and the regulators evaluating your drugs) less useful data to work with"
Derek Lowe, In the pipeline.

science.org/content/blog-post/

Show older
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.